A Clinical trial on Arugampul veer kudeneer in the management of Kalladaippu (Urolithiasis)

A PROSPECTIVE OPEN LABELLED, SINGLE ARM, NON RANDOMISED SINGLE CENTRIC, PHASE II CLINICAL TRIAL ON ARUGAMPUL VER KUDENEER IN THE MANAGEMENT OF KALLADAIPPU NOI(UROLITHIASIS)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/07/054789

Enrollment

Registered

2023-07-05

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N209- Urinary calculus, unspecified

Interventions

Intervention1: ARUGAMPUL VEER KUDENEER: 30_60ml/ twice day(orally) Intervention2: ARUGAMPUL VEER KUDENEER: Dosage: 30-60 ml Frequency: twice a day Duration: 45 days Control Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: Patient with the symptoms of Renal colicky pain Loin to groin pain Nausea Vomiting and sweating Hematuria Oliguria Dysuria

Exclusion criteria

Exclusion criteria: Chronic Appendicitis Cholecystitis Pelvic inflammatory disease Chronic Renal Failure Bilateral obstructive uropathy

Design outcomes

Primary

Measure	Time frame
Reduction in severity of Renal colicky pain, Reduction of Nausea/vomiting Reduction of Hematuria, Polyuria, Dysuria and Oliguria. The kidney stone is expelled to come out as such or be disintegrated and mixed with urine will be ensured.Timepoint: 45 days	—

Secondary

Measure	Time frame
The secondary outcome is reduction in size of the kidney stone in USG abdomen and pelvis.Timepoint: 45days	—

Countries

India

Contacts

Public ContactProf Dr Manoharan MDS PhD

Government Siddha Medical College and Hospital

justusantony71@gmail.com9443090849

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026